Tech Company Financing Transactions
ElevateBio Funding Round
ElevateBio, operating out of Cambridge, received $401 million from Matrix Capital Management, EcoR1 Capital Management and Edbi.
Transaction Overview
Company Name
Announced On
5/24/2023
Transaction Type
Venture Equity
Amount
$401,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to further advance its technology platforms Life Edit and BaseCamp.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
139 Main St. 500
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
ElevateBio is creating and operating a portfolio of cell and gene therapy companies through partnerships with the world's most innovative scientists and inventors. Together, we leverage our internal bench-to-bedside expertise and to accelerate the development and delivery of therapies -- supported by our broad access to capital.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hallal
Chief Financial Officer
Vikas Sinha
Chief Scientific Officer
Mitchell Finer
VP - Bus. Development
David Backer
VP - Bus. Development
Stacey Hero
VP - Bus. Development
Agustin Melian
VP - Bus. Development
Jeroen van Beek
VP - Engineering
Mario Miele
VP - Finance
Bhakti Bhargava
VP - General Counsel
Edward Miller
VP - Human Resources
Missy Kotchey
VP - Operations
Michael Paglia
VP - Regulatory Affairs
Douglas Chambers
VP - Regulatory Affairs
Josh Sorafine
Browse more venture capital transactions:
Prev: 5/24/2023: Opus Training venture capital transaction
Next: 5/24/2023: DataOps.live venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs